Lexaria Bioscience Corp (LEXX) - Net Assets
Based on the latest financial reports, Lexaria Bioscience Corp (LEXX) has net assets worth $4.52 Million USD as of November 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.05 Million) and total liabilities ($1.53 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Lexaria Bioscience Corp (LEXX) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $4.52 Million |
| % of Total Assets | 74.76% |
| Annual Growth Rate | 4.45% |
| 5-Year Change | -80.08% |
| 10-Year Change | 2865.87% |
| Growth Volatility | 672.81 |
Lexaria Bioscience Corp - Net Assets Trend (2005–2025)
This chart illustrates how Lexaria Bioscience Corp's net assets have evolved over time, based on quarterly financial data. Also explore Lexaria Bioscience Corp asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Lexaria Bioscience Corp (2005–2025)
The table below shows the annual net assets of Lexaria Bioscience Corp from 2005 to 2025. For live valuation and market cap data, see LEXX market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-08-31 | $2.60 Million | -66.02% |
| 2024-08-31 | $7.66 Million | +185.78% |
| 2023-08-31 | $2.68 Million | -64.89% |
| 2022-08-31 | $7.63 Million | -41.57% |
| 2021-08-31 | $13.06 Million | +426.28% |
| 2020-08-31 | $2.48 Million | -0.34% |
| 2019-08-31 | $2.49 Million | +4.29% |
| 2018-08-31 | $2.39 Million | -13.72% |
| 2017-08-31 | $2.77 Million | +3053.97% |
| 2016-08-31 | $87.76K | -86.63% |
| 2015-08-31 | $656.60K | -68.72% |
| 2014-08-31 | $2.10 Million | 0.00% |
| 2013-08-31 | $2.10 Million | -5.67% |
| 2012-08-31 | $2.23 Million | -16.39% |
| 2011-08-31 | $2.66 Million | +11.42% |
| 2010-08-31 | $2.39 Million | +8.32% |
| 2009-08-31 | $2.21 Million | -10.43% |
| 2008-08-31 | $2.46 Million | -27.48% |
| 2007-08-31 | $3.39 Million | +381.85% |
| 2006-08-31 | $704.55K | -35.32% |
| 2005-08-31 | $1.09 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Lexaria Bioscience Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6338489100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (August 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $19.56K | 0.65% |
| Other Comprehensive Income | $-70.33K | -2.35% |
| Other Components | $66.50 Million | 2224.34% |
| Total Equity | $2.99 Million | 100.00% |
Lexaria Bioscience Corp Competitors by Market Cap
The table below lists competitors of Lexaria Bioscience Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Asuransi Jasa Tania Tbk
JK:ASJT
|
$15.50 Million |
|
Macompta Fr Sa
PA:MLMCA
|
$15.50 Million |
|
Electro-Sensors Inc
NASDAQ:ELSE
|
$15.51 Million |
|
Megapolitan Developments Tbk
JK:EMDE
|
$15.51 Million |
|
Alexium International Group Ltd
AU:AJX
|
$15.49 Million |
|
Botala Energy Ltd
AU:BTE
|
$15.48 Million |
|
Stradim Espace Finances SA
PA:ALSAS
|
$15.48 Million |
|
Argenica Therapeutics Ltd
AU:AGN
|
$15.45 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lexaria Bioscience Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 8,036,400 to 2,989,697, a change of -5,046,703 (-62.8%).
- Net loss of 11,901,841 reduced equity.
- New share issuances of 6,046,163 increased equity.
- Other comprehensive income decreased equity by 50,519.
- Other factors increased equity by 859,494.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-11.90 Million | -398.1% |
| Share Issuances | $6.05 Million | +202.23% |
| Other Comprehensive Income | $-50.52K | -1.69% |
| Other Changes | $859.49K | +28.75% |
| Total Change | $- | -62.80% |
Book Value vs Market Value Analysis
This analysis compares Lexaria Bioscience Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.28x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.10x to 4.28x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-08-31 | $6.81 | $0.71 | x |
| 2006-08-31 | $4.38 | $0.71 | x |
| 2007-08-31 | $16.76 | $0.71 | x |
| 2008-08-31 | $11.23 | $0.71 | x |
| 2009-08-31 | $8.21 | $0.71 | x |
| 2010-08-31 | $5.29 | $0.71 | x |
| 2011-08-31 | $5.40 | $0.71 | x |
| 2012-08-31 | $3.69 | $0.71 | x |
| 2013-08-31 | $3.48 | $0.71 | x |
| 2014-08-31 | $0.08 | $0.71 | x |
| 2015-08-31 | $0.58 | $0.71 | x |
| 2016-08-31 | $0.18 | $0.71 | x |
| 2017-08-31 | $1.53 | $0.71 | x |
| 2018-08-31 | $1.01 | $0.71 | x |
| 2019-08-31 | $0.92 | $0.71 | x |
| 2020-08-31 | $0.91 | $0.71 | x |
| 2021-08-31 | $3.02 | $0.71 | x |
| 2022-08-31 | $1.35 | $0.71 | x |
| 2023-08-31 | $0.46 | $0.71 | x |
| 2024-08-31 | $0.65 | $0.71 | x |
| 2025-08-31 | $0.17 | $0.71 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lexaria Bioscience Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -398.10%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1686.00%
- • Asset Turnover: 0.17x
- • Equity Multiplier: 1.40x
- Recent ROE (-398.10%) is below the historical average (-123.67%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | -46.66% | -2502.86% | 0.02x | 1.01x | $-617.19K |
| 2006 | -149.87% | -417.10% | 0.09x | 3.86x | $-1.13 Million |
| 2007 | -28.82% | -108.63% | 0.24x | 1.12x | $-1.32 Million |
| 2008 | -30.61% | -178.59% | 0.13x | 1.32x | $-999.77K |
| 2009 | -25.05% | -152.42% | 0.11x | 1.55x | $-772.99K |
| 2010 | -22.53% | -47.47% | 0.29x | 1.62x | $-777.09K |
| 2011 | -9.45% | -18.52% | 0.31x | 1.63x | $-517.64K |
| 2012 | -15.44% | -31.30% | 0.30x | 1.66x | $-566.07K |
| 2013 | -16.37% | -31.30% | 0.31x | 1.70x | $-553.44K |
| 2014 | -89.15% | -170.50% | 0.31x | 1.70x | $-2.08 Million |
| 2015 | -229.22% | -12042.58% | 0.02x | 0.92x | $-1.85 Million |
| 2016 | -456.60% | -2983.38% | 0.07x | 2.13x | $-1.24 Million |
| 2017 | -62.18% | -2937.31% | 0.02x | 0.95x | $-2.17 Million |
| 2018 | -276.31% | -1522.97% | 0.18x | 1.02x | $-6.84 Million |
| 2019 | -172.02% | -1841.53% | 0.08x | 1.12x | $-4.34 Million |
| 2020 | -155.79% | -1249.71% | 0.11x | 1.12x | $-4.19 Million |
| 2021 | -30.36% | -557.19% | 0.05x | 1.00x | $-5.35 Million |
| 2022 | -91.45% | -2846.30% | 0.03x | 0.99x | $-8.06 Million |
| 2023 | -218.94% | -2946.36% | 0.07x | 1.01x | $-6.97 Million |
| 2024 | -72.11% | -1248.25% | 0.05x | 1.10x | $-6.60 Million |
| 2025 | -398.10% | -1686.00% | 0.17x | 1.40x | $-12.20 Million |
Industry Comparison
This section compares Lexaria Bioscience Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Lexaria Bioscience Corp (LEXX) | $4.52 Million | -46.66% | 0.34x | $15.49 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Lexaria Bioscience Corp
Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall … Read more